$RCEL

AVITA Medical, Inc.

AVITA Medical develops and commercializes medical devices and wound care products for acute wound management, serving clinicians and healthcare facilities including burn, trauma and surgical centers. Its portfolio includes RECELL, an autologous cell harvesting system that prepares a suspension of a patient’s skin cells for treating thermal burns and full-thickness skin defects; RECELL GO and RECELL GO mini are versions designed for different wound sizes. The company also offers Cohealyx, a collagen-based dermal matrix for wound bed preparation, and PermeaDerm, a biosynthetic wound matrix used for wound coverage during healing. AVITA Medical makes and sells RECELL and PermeaDerm, and markets and distributes Cohealyx under an exclusive agreement. It sells directly to U.S. customers and uses third-party distributors internationally. The company is headquartered in Valencia, California.

2
2
0

No SEC Form 4 filings for $RCEL in the last 30 days.

See all $RCEL insider activity →
Low

AVITA Medical, Inc. (RCEL) Reports Cohealyx I Mean Graft Readiness at 13.6 Days

AVITA Medical reported final Cohealyx I study results, with a mean graft readiness time of 13.6 days, beating the 28-day goal. Six-month follow-up in 40 patients showed healing, improved scar scores, and no adverse events. The company noted no new product launch, only extended results from April.

AVITA Medical Issues 267,533 Shares in Cashless Warrant Exercises

AVITA Medical (RCEL) issued 267,533 shares following cashless warrant exercises by Perceptive and OrbiMed. Perceptive received 119,375 shares, while OrBiMed received 148,158 shares. The exercises were disclosed in filings with the Australian Securities Exchange on November 13, 2026.

AVITA Medical, Inc. lodged certain filings on the Australian Securities Exchange disclosing the following two exercises of previously disclosed warrants

AVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Regulation FD Disclosure. On November 13 2026, AVITA Medical, Inc. (the “Company”) lodged certain filings on the Australian Securities Exchange (the “ASX”) disclosing the following two exercises of previously disclosed warrants: Perceptive Credit Holdings V, LP (“Percep

RCEL sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning RCEL (AVITA Medical, Inc.). Coverage has skewed bullish: 2 bullish, 2 neutral, and 0 bearish.

Recent RCEL coverage spans earnings, corporate actions and financial news.

What's driving RCEL

  • Positive trial data may improve sentiment and attract interest from investors focused on wound‑care biotech.

    tradingview.com · Nov 16, 2026

  • The warrant exercises increase share count, modestly diluting existing shareholders.

    tradingview.com · Nov 13, 2026

  • Warrant exercises increase share count and can slightly pressure near-term per-share metrics, but the filing is mainly capital-structure housekeeping tied to prior financing.

    SEC EDGAR 8-K · Nov 13, 2026

  • Analyst upgrade and higher target suggest upside potential.

    investing.com · Nov 12, 2026

  • AVITA Medical Inc reported Q3 2026 revenue of $26.1M, up 53% YoY, with U.S. Resell revenue rising 20% sequentially. Gross margin expanded to 84%, and operating expenses remained flat. Full-year revenue guidance was raised to $92M-$94M. Q3 growth may have included $1M from seasonal factors, and Q4 guidance suggests potential deceleration. The company expects cash flow breakeven in Q4 and flat operating expenses in 2027, with growth driven by new reimbursement frameworks and product adoption.

    finance.yahoo.com · Nov 6, 2026

AlphAI scores every news story that mentions RCEL with an AI model for sentiment and relevance, and aggregates insider trades from AVITA Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $RCEL

Score

AVITA Medical, Inc. lodged certain filings on the Australian Securities Exchange disclosing the following two exercises of previously disclosed warrants

AVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Regulation FD Disclosure. On November 13 2026, AVITA Medical, Inc. (the “Company”) lodged certain filings on the Australian Securities Exchange (the “ASX”) disclosing the following two exercises of previously disclosed warrants: Perceptive Credit Holdings V, LP (“Percep

AVITA Medical Inc (AVHHL) (Q3 2026) Earnings Call Highlights: Revenue Surges 53%

AVITA Medical Inc reported Q3 2026 revenue of $26.1M, up 53% YoY, with U.S. Resell revenue rising 20% sequentially. Gross margin expanded to 84%, and operating expenses remained flat. Full-year revenue guidance was raised to $92M-$94M. Q3 growth may have included $1M from seasonal factors, and Q4 guidance suggests potential deceleration. The company expects cash flow breakeven in Q4 and flat operating expenses in 2027, with growth driven by new reimbursement frameworks and product adoption.

$RCELMedEarnings

AVITA Medical Reports Third Quarter Results

AVITA Medical, Inc. (RCEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AVITA Medical Reports Third Quarter Results Delivers Strong Q3 With 53% Year-Over-Year Revenue Growth Raises Full Year 2026 Revenue Guidance VALENCIA, Calif., November 5, 2026 (GLOBE NEWSWIRE) — AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic a

Related tickers